Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
Yanaoka K, Oka M, Yoshimura N, Mukoubayashi C, Enomoto S, Iguchi M, Magari H, Utsunomiya H, Tamai H, Arii K, Yamamichi N, Fujishiro M, Takeshita T, Mohara O, Ichinose M. Yanaoka K, et al. Among authors: yoshimura n. Int J Cancer. 2008 Aug 15;123(4):917-26. doi: 10.1002/ijc.23571. Int J Cancer. 2008. PMID: 18508314 Free article.
Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels.
Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Inoue I, Iguchi M, Maekita T, Ueda K, Utsunomiya H, Tamai H, Fujishiro M, Iwane M, Takeshita T, Mohara O, Ichinose M. Yanaoka K, et al. Among authors: yoshimura n. Int J Cancer. 2009 Dec 1;125(11):2697-703. doi: 10.1002/ijc.24591. Int J Cancer. 2009. PMID: 19610064 Free article.
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
Yanaoka K, Oka M, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Maekita T, Inoue I, Ueda K, Utsunomiya H, Iguchi M, Tamai H, Fujishiro M, Nakamura Y, Tsukamoto T, Inada K, Takeshita T, Ichinose M. Yanaoka K, et al. Among authors: yoshimura n. Int J Cancer. 2010 Mar 15;126(6):1467-73. doi: 10.1002/ijc.24862. Int J Cancer. 2010. PMID: 19711347 Free article. Clinical Trial.
Elevated risk of colorectal adenoma with Helicobacter pylori-related chronic gastritis: a population-based case-control study.
Inoue I, Mukoubayashi C, Yoshimura N, Niwa T, Deguchi H, Watanabe M, Enomoto S, Maekita T, Ueda K, Iguchi M, Yanaoka K, Tamai H, Arii K, Oka M, Fujishiro M, Takeshita T, Iwane M, Mohara O, Ichinose M. Inoue I, et al. Among authors: yoshimura n. Int J Cancer. 2011 Dec 1;129(11):2704-11. doi: 10.1002/ijc.25931. Epub 2011 Mar 8. Int J Cancer. 2011. PMID: 21225622 Free article.
Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
Watanabe M, Kato J, Inoue I, Yoshimura N, Yoshida T, Mukoubayashi C, Deguchi H, Enomoto S, Ueda K, Maekita T, Iguchi M, Tamai H, Utsunomiya H, Yamamichi N, Fujishiro M, Iwane M, Tekeshita T, Mohara O, Ushijima T, Ichinose M. Watanabe M, et al. Among authors: yoshimura n. Int J Cancer. 2012 Dec 1;131(11):2632-42. doi: 10.1002/ijc.27514. Epub 2012 Mar 28. Int J Cancer. 2012. PMID: 22383377 Free article.
Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, Oka M, Watanabe M, Enomoto S, Niwa T, Maekita T, Iguchi M, Tamai H, Utsunomiya H, Yamamichi N, Fujishiro M, Iwane M, Takeshita T, Ushijima T, Ichinose M. Yoshida T, et al. Among authors: yoshimura n. Int J Cancer. 2014 Mar 15;134(6):1445-57. doi: 10.1002/ijc.28470. Epub 2013 Oct 3. Int J Cancer. 2014. PMID: 24009139 Free article.
Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography.
Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Tamai H, Arii K, Nakata H, Yoshimura N, Takeshita T, Miki K, Mohara O, Ichinose M. Ohata H, et al. Among authors: yoshimura n. Cancer Sci. 2005 Oct;96(10):713-20. doi: 10.1111/j.1349-7006.2005.00098.x. Cancer Sci. 2005. PMID: 16232204 Free article. Clinical Trial.
Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males.
Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, Magari H, Utsunomiya H, Tamai H, Arii K, Ohata H, Fujishiro M, Takeshita T, Mohara O, Ichinose M. Yanaoka K, et al. Among authors: yoshimura n. Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):838-45. doi: 10.1158/1055-9965.EPI-07-2762. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18398025 Clinical Trial.
2,438 results